180 related articles for article (PubMed ID: 27557389)
21. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.
Kwong YL; Anderson BO; Advani R; Kim WS; Levine AM; Lim ST;
Lancet Oncol; 2009 Nov; 10(11):1093-101. PubMed ID: 19880063
[TBL] [Abstract][Full Text] [Related]
22. UK CLL Forum, London, 25th October 2001.
Hamblin TJ
Leuk Res; 2002 Jun; 26(6):607-9. PubMed ID: 12007510
[No Abstract] [Full Text] [Related]
23. Changing therapeutic landscape--the last decade.
Aurer I
Transfus Apher Sci; 2011 Apr; 44(2):155-9. PubMed ID: 21320799
[TBL] [Abstract][Full Text] [Related]
24. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K; Bernhardt B; Strickland B
Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
[TBL] [Abstract][Full Text] [Related]
25. Emerging targeted therapies for pediatric acute myeloid leukemia.
Masetti R; Kleinschmidt K; Biagi C; Pession A
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):354-66. PubMed ID: 21635222
[TBL] [Abstract][Full Text] [Related]
26. Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center.
Tanyildiz HG; Dincaslan H; Yavuz G; Unal E; Ikinciogulları A; Dogu F; Tacyildiz N
J Clin Immunol; 2016 Oct; 36(7):667-76. PubMed ID: 27492260
[TBL] [Abstract][Full Text] [Related]
27. Lymphoproliferative disorders after liver transplantation.
Leblond V; Choquet S
J Hepatol; 2004 May; 40(5):728-35. PubMed ID: 15094218
[No Abstract] [Full Text] [Related]
28. Post-transplant lymphoproliferative disorders.
Singavi AK; Harrington AM; Fenske TS
Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
[TBL] [Abstract][Full Text] [Related]
29. [Innovative antibody-therapies for malignant lymphomas].
Müller AM; Rawluk J; Thierry V; Brink I; Engelhardt M
Dtsch Med Wochenschr; 2005 Dec; 130(48):2783-8. PubMed ID: 16307409
[TBL] [Abstract][Full Text] [Related]
30. [Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].
Szegedi I; Gáspár I; Gyurina K; Zele Z; Kiss C
Magy Onkol; 2018 Dec; 62(4):204-213. PubMed ID: 30540862
[TBL] [Abstract][Full Text] [Related]
31. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
32. Antibody therapy in aggressive lymphomas.
Habermann TM
Hematology Am Soc Hematol Educ Program; 2007; ():257-64. PubMed ID: 18024638
[TBL] [Abstract][Full Text] [Related]
33. Emerging immunotherapy in pediatric lymphoma.
Erker C; Harker-Murray P; Burke MJ
Future Oncol; 2016 Jan; 12(2):257-70. PubMed ID: 26616565
[TBL] [Abstract][Full Text] [Related]
34. Novel agents and future directions for refractory breast cancer.
Burstein HJ
Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
[TBL] [Abstract][Full Text] [Related]
35. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
36. Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder.
Batchelor TT; Thye LS; Habermann TM
Am Soc Clin Oncol Educ Book; 2016; 35():e354-66. PubMed ID: 27249742
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies in the treatment of malignant lymphomas.
Coiffier B
Adv Exp Med Biol; 2008; 610():155-76. PubMed ID: 18593022
[No Abstract] [Full Text] [Related]
38. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
39. New drugs for aggressive B-cell and T-cell lymphomas.
Murawski N; Pfreundschuh M
Lancet Oncol; 2010 Nov; 11(11):1074-85. PubMed ID: 21051020
[TBL] [Abstract][Full Text] [Related]
40. Clinical course and therapeutic implications for lymphoid malignancies in Nijmegen breakage syndrome.
Pastorczak A; Szczepanski T; Mlynarski W;
Eur J Med Genet; 2016 Mar; 59(3):126-32. PubMed ID: 26826318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
